Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort

General Hospital Psychiatry

Volumn 29, Issue 3, 2007, Pages 251-256

  Levin, Tomer T ^a   Li, Yuelin ^a   Riskind, John ^b   Rai, Kanti ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Anxiety; Chronic lymphocytic leukemia; Depression; Quality of life

Indexed keywords

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEPRESSION; EMOTIONALITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL CAPACITY; PHYSICAL CAPACITY; QUALITY OF LIFE; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY;

ADULT; AGE DISTRIBUTION; AGED; ANXIETY; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEW YORK; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 34247560286     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2007.01.014     Document Type: Article

References (27)

1. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 46 12 (2005) 1909-1914
2. Redaelli A., et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 13 3 (2004) 279-287
3. Chiorazzi N., Rai K., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 8 (2005) 804-815
4. Rai K., and Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 348 348 (2003) 1797-1799
5. Cheson B., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 12 (1996) 4990-4997
6. Dighiero G., et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338 21 (1998) 1506-1514
7. Rai K., et al. Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 18 (2004) 795-805
8. Holzner B., et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 72 6 (2004) 381-389
9. Haber J., et al. Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases - chronic lymphadenosis and multiple myeloma. Vnitr Lek 42 (1996) 262-267
10. Siakantaris M., et al. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma 40 (2000) 141-147
11. Osterborg A., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20 (2002) 2486-2494
12. Holzner B., et al. Quality of life measurement in oncology - a matter of the assessment instrument?. Eur J Cancer 37 18 (2001) 2349-2356
13. Beck A., Ward C., and Mendelson M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 4 (1961) 561-571
14. Beck A.T., et al. An inventory for measuring clinical anxiety - psychometric properties. J Consult Clin Psychol 56 6 (1988) 893-897
15. Webster K., et al. Measuring the quality of life (QOL) in patients with non-Hodgkin's lymphoma (NHL): the functional assessment of cancer therapy. Qual Life Res 14 (2005) 2103
16. Ware J., Gandek B., and IQOLA-Project-Group. The SF-36 Health Survey: development and use in mental health research and the IQOLA Project. Int J Ment Health 23 2 (1994) 49-73
17. Spitzer R., Kroenke K., and Williams J. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 282 18 (1999) 1737-1744
18. Brucker P., et al. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28 2 (2005) 192
19. Maxwell S.E., and Delaney H.D. Bivariate median splits and spurious statistical significance. Psychol Bull 113 1 (1993) 181
20. Zabora J., et al. The prevalence of psychological distress by cancer site. Psychooncology 10 1 (2001) 19
21. Ware J.E., Kosinski M., and Dewey J.E. How to score version 2 of the SF-36 Health Survey (2002), Quality Metric Inc, Lincoln (RI) 231
22. Levin T.T., and Kissane D.W. Psychooncology: the state of its development in 2006. Eur J Psychiatry 20 3 (2006) 183-197
23. Carver C.S., et al. Optimistic personality and psychosocial well-being during treatment predict psychosocial well-being among long-term survivors of breast cancer. Health Psychol 24 5 (2005) 508-516
24. Rabkin J.G., et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 65 1 (2005) 62-67
25. Schapira M.M., et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care 39 3 (2001) 243
26. Litwin M.S., et al. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the cancer of the prostate strategic urologic research endeavor?. Cancer 95 1 (2002) 54
27. Koedoot C., et al. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting. Eur J Cancer 40 2 (2004) 225